Search

Nicholas Smith (University at Buffalo) and Dwayne Roach (San Diego State University) received a $3.6 million NIH grant to study pharmacokinetics and pharmacodynamics of mechanistically aware phage cocktails.

Associate Professor Jeremy Barr (Monash University) received $500,000 USD from the Bill & Melinda Gates Foundation to investigate how phages interact with the human immune system and their potential implications for treating inflammatory di

The Leo Foundation has granted 4 million DKK to a new innovative phage therapy project led by Thomas Sicheritz-Pontén (University of Copenhagen), aiming to combat necrotizing soft tissue infections by harnessing Group A Strep-targeting phag

Yves Briers will head up Obulytix, a new company based on the phage lysin-based platform leveraging AI to tackle bacterial infections he co-developed at Ghent University and KU Leuven. Obulytix has already attracted $4 M Euro investment fro

Eligo Bioscience has raised $30 million to advance and test their CRISPR-based medicine for acne vulgaris and develop their platform for other diseases. Congrats Eligo!

Congrats to Vivek Mutalik and colleagues, who have received funding from the BRaVE initiative (US Dept of Energy) to expand their Phage Foundry, a platform for phage countermeasures against AMR pathogens.

The Phage Australia team at the Westmead Institute for Medical Research has been awarded $3.5 million by the NSW Government to address the phage manufacturing bottleneck for phage therapy patients.

University of Toronto has received a $5 million dollar gift to start a phage therapy center in Canada, to be led by infectious disease microbiologist Greg German MD, PhD. It will include creation of a professorship in phage therapy research

Fixed Phage, a biotechnology company based in Glasgow, has secured £1.5 million in funding to further develop and commercialize its phage technology.

Phagos, a French phage manufacturing company, announced the closing of a €2.4 million Seed investment round co-led by Demeter (Paris) and Hoxton Ventures (London).

Adaptive Phage Therapeutics (APT) has announced that the Defense Health Agency (DHA) has awarded an additional $5 million to support clinical development of APT’s adaptive bacteriophage therapy in treatment of diabetic foot osteomyelitis (D

Phase Genomics raised $5.5M from the Bill and Melinda Gates Foundation & NIH to catalog the viruses that infect bacteria. The resulting database could be used to develop new therapeutics & build a surveillance system to detect & respond to

IPATH is honored to announce that the Mallory Smith Legacy Fund has directed another generous gift of $50,000 to IPATH that will help to fund important phage therapy research focused on cystic fibrosis patients.

Funding: The AMR Action fund has invested $20 million in Adaptive Phage Therapeutics. Congrats APT!

Adaptive Phage Therapeutics was awarded an additional $8 Million from the U.S. Department of Defense (DoD) for the continued development of phage therapies for the treatment of infectious diseases. The new funding brings the total DoD contr

Felix Biotechnology was awarded an NSF Small Business Innovation Research (SBIR) Phase I grant for $256,000 to further enhance their machine learning-based approach for engineering phage as a novel treatment for drug-resistant bacterial inf

Proteon Pharmaceuticals announced an investment of 21 million Euro to accelerate commercialization of its phage products, which aim to reduce reliance on antibiotics in aquaculture and livestock farming, improve on-farm performance and incr

Biochimpharm, a Georgian phage biotech company, has been awarded a $150,000 grant from the EU and the United Nations FAO to support production of PowerPhage, a phage cocktail product that targets Salmonella, E. coli and Shigella, for veteri

Adaptive Phage Therapeutics (APT), a clinical-stage US biotech company, just closed a $40.75 million Series B investment round led by Deerfield Management Company (and also including Mayo Clinic). This will enable APT to accelerate clinical

Dr. Evelien Adriaenssens and Dr. Matthew Gilmour (Quadram Institute, Norwich, UK) have won BBSRC partnership awards to collaborate with Canadian researchers! Dr. Adriaenssens’ partnership is with Dr. Hany Anany's lab at Agriculture and Agri